In an explicit effort to bring approved cell and gene therapies (CGT) to patients sooner, FDA has launched a number of initiatives and programs to address the pace of CGT approvals. In this article for Cell & Gene, Sidley’s Emily Marden and Kelly Cho share their insights on key regulatory developments relevant to sponsors seeking regulatory approval of CGTs for commercialization in the U.S.
View article here.
